Thematic Take

Powered by

Get ready for ESG 2.0

As ESG becomes ever more important for business, how can companies in the pharma sector adjust?

Theme briefing

How to prepare for mandatory ESG reporting

Expert view

GlobalData analyst on net-zero strategy for businesses

Feature

Solving sustainability challenges in rare disease trials

Feature

Can pharma overcome generative AI’s bias problem?

06/04/2024 13:18:51
  • Home | Lula’s progress plan for Brazil: A year on
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Xylem
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Trends & Insight
  • phasetwo
  • Datwyler Company Insight
  • Datwyler
  • In Depth
  • Lula’s progress plan for Brazil: A year on
  • How sham patents are hurting the pharma industry
  • Tracking the opioid lawsuit settlements amidst calls for oversight
  • Cell and gene therapy landscape in the US
  • Q&A: Cell and gene therapy value assessments need a rework to allow access
  • Pharmaceutical discovery through a gravitational lens
  • Thematic Take: ESG
  • Thematic Take: contents
  • Foreword: A growing sense of urgency in ESG
  • ESG 1.0 is over – get ready for ESG 2.0
  • ESG becomes mandatory: how to prepare
  • Theme timeline: the past, present and future of ESG
  • Net-zero strategies for the pharma sector
  • Leading pharma companies and initiatives in the race for net zero
  • GlobalData’s Christopher Papadopoullos on net-zero strategy for businesses
  • 38% of companies lack an ESG strategy – GlobalData survey
  • Sustainability challenges in rare disease trials remain, but change is happening
  • ESCMID 2024: The infectious consequences of climate change
  • Bring your own device: How patients own tech is being used in clinical trials
  • Can pharma overcome generative AI’s bias problem?
  • China-US tensions are spilling into the biotech sector
  • Japanese patients among least empowered in the developed world
  • World Air Quality Report: what are the health impacts and where is it worst?
  • Why has New Zealand U-turned on the world’s first smoking ban?
  • Microplastics in placentas: how serious is the problem?
  • Deal activity related to ESG in the pharma industry since 2021
  • GlobalData Thematic Intelligence
  • Sponsored Supplements
  • BEA Technologies
  • Cytiva
  • Listings
  • Events
  • Innovation Rankings
  • Buyer's Guides
  • Next issue
05/22/2024 00:00:00